Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Chiahsuan Chin"'
Autor:
Charles B Stauft, Chen Yang, J Robert Coleman, David Boltz, Chiahsuan Chin, Anna Kushnir, Steffen Mueller
Publikováno v:
PLoS ONE, Vol 14, Iss 10, p e0223784 (2019)
Currently, influenza vaccine manufacturers need to produce 1-5 x 107 PFU of each vaccine strain to fill one dose of the current live-attenuated-influenza-vaccine (LAIV). To make a single dose of inactivated vaccine (15 ug of each hemagglutinin), the
Externí odkaz:
https://doaj.org/article/73ad1e00cc2342e1a115bbc7b97ebe66
Autor:
Chiahsuan Chin, Ranjithkumar Ravichandran, Kristina Sanborn, Timothy Fleming, Stephen B. Wheatcroft, Mark T. Kearney, Sofya Tokman, Rajat Walia, Michael A. Smith, David J. Flint, Thalachallour Mohanakumar, Ross M. Bremner, Angara Sureshbabu
Publikováno v:
Cell Reports Medicine. 4:100945
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c05b6b04094fc6142786046171178428
https://doi.org/10.1016/j.xcrm.2023.100945
https://doi.org/10.1016/j.xcrm.2023.100945
Autor:
Yoshihiro Itabashi, Ranjithkumar Ravichandran, Sandhya Bansal, Chiahsuan Chin, Christin Poulson, Angara Sureshbabu, Sumi Sukumaran Nair, Sudhir Perincheri, T. Mohanakumar
Publikováno v:
Transplant Immunology. 75:101702
Antibodies against donor human leukocyte antigen are a risk factor for chronic immune injury (CII) following renal transplantation; however, it is often not detectable. The main goal of this study is to gain new insights into the kinetics of exosome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::651a1e391f79b7d9975f3c9212977110
https://doi.org/10.1016/j.trim.2022.101702
https://doi.org/10.1016/j.trim.2022.101702
Publikováno v:
Cytokinegrowth factor reviews. 57
Fibrosis leads to destruction of organ architecture accompanied by chronic inflammation and loss of function. Fibrosis affects nearly every organ in the body and accounts for ∼45% of total deaths worldwide. Over the past decade, tremendous progress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dce81aa6950bb39b77b2272b1ee0ce0
https://pubmed.ncbi.nlm.nih.gov/32900600
https://pubmed.ncbi.nlm.nih.gov/32900600
Autor:
Steffen Mueller, Anna Kushnir, J. Robert Coleman, Chen Yang, Chiahsuan Chin, David Boltz, Charles B. Stauft
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 10, p e0223784 (2019)
PLoS ONE, Vol 14, Iss 10, p e0223784 (2019)
Currently, influenza vaccine manufacturers need to produce 1-5 x 107 PFU of each vaccine strain to fill one dose of the current live-attenuated-influenza-vaccine (LAIV). To make a single dose of inactivated vaccine (15 ug of each hemagglutinin), the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4be75587f84f74d3058692270f50d2a1
http://europepmc.org/articles/PMC6791556
http://europepmc.org/articles/PMC6791556